Analyst Price Target is $15.75
▲ +156.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MiMedx Group in the last 3 months. The average price target is $15.75, with a high forecast of $23.00 and a low forecast of $8.50. The average price target represents a 156.93% upside from the last price of $6.13.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in MiMedx Group.
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matri derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.